

Instructions For Use RA0051-C.5-IFU-RUO

**Revision: 1** 

Rev. Date: Sept. 30, 2014

Page 1 of 2

P.O. Box 3286 - Logan, Utah 84323, U.S.A. - Tel. (800) 729-8350 - Tel. (435) 755-9848 - Fax (435) 755-0015 - www.scytek.com

# CD30 / TNFRSF8 (Hodgkin & Reed-Sternberg Cell Marker); Clone Ber-H2 & CD30/412 (Concentrate)

Availability/Contents:	<u>Item #</u>
Description:	
Species:	Mouse
Immunogen:	Cancer cell line established from a patient with Hodgkin's disease of T-cell lineage (Ber-H2); human CD30 recombinant protein (CD30/412)
Clone:	Ber-H2 & CD30/412
Isotype:	lgG1, kappa (Ber-H2); lgG1, kappa (CD30/412)
Entrez Gene ID:	943 (Human)
Hu Chromosome Loc.:	1p36.22
Synonyms:	CD30L receptor, Cytokine receptor CD30, Ki-1 antigen, Lymphocyte activation antigen CD30, Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)
Mol. Weight of Antigen:	105-120kDa
Format:	Tissue culture supernatant with 0.05% Azide.
Specificity:	Recognizes a single chain glycoprotein of 105/120kDa, identified as CD30/Ki-1. This MAb distinguishes large cell lymphomas derived from activated lymphoid cells from histiocytic malignancies and lymphomas derived from resting and precursor lymphoid cells or from anaplastic carcinomas.
Background:	CD30 is synthesized as a 90kDa precursor, which is processed in the Golgi complex into a membrane-bound phosphorylated mature 105/120kDa glycoprotein. In Hodgkin's disease, CD30/Ki-1 antigen is expressed by mononuclear-Hodgkin and multinucleated Reed-Sternberg cells. It is also expressed by the tumor cells of a majority of anaplastic large cell lymphomas as well as by a varying proportion of activated T- and B-cells. About one third of the Ki-1 positive lymphomas lack the leukocyte common antigen (CD45).
Species Reactivity:	Human. Others not known.
Positive Control:	Hodgkin's lymphoma
Cellular Localization:	Cell surface
Titer/ Working Dilution:	Immunohistochemistry (Frozen and Formalin-fixed): 1:100-1:200 Flow Cytometry: 5-10 μl/million cells Immunofluorescence: 1:50-1:100
Microbiological State:	This product is not sterile.







EC REPEmergoEurope (31)(0) 70 345-8570Molsnstraat 152513 BH Hague, The Netherlands

Doc: IFU-Template2-8rev2



## Instructions For Use RA0051-C.5-IFU-RUO

Rev. Date: Sept. 30, 2014


Revision: 1 Page 2 of 2

P.O. Box 3286 - Logan, Utah 84323, U.S.A. - Tel. (800) 729-8350 - Tel. (435) 755-9848 - Fax (435) 755-0015 - www.scytek.com

**Uses/Limitations:** 

Not to be taken internally. For Research Use Only. This product is intended for qualitative immunohistochemistry with normal and neoplastic formalin-fixed, paraffin-embedded tissue sections, to be viewed by light microscopy. Do not use if reagent becomes cloudy. Do not use past expiration date. Non-Sterile.

## Ordering Information and Current Pricing at www.scytek.com



Formalin-paraffin human Hodgkin's lymphoma stained with CD30; Clone Ber-H2 & CD30/412.

#### Procedure:

- 1. **Tissue Section Pretreatment (Required):** Staining of formalin fixed, paraffin embedded tissue sections is significantly enhanced by pretreatment with EDTA Buffer (10X) HIER Solution (pH 8.0) (ScyTek catalog# ETA).
- Primary Antibody Incubation Time: We suggest an incubation period of 30 minutes at room temperature. However, depending upon the fixation conditions and the staining system employed, optimal incubation should be determined by the user.
- 3. **Visualization:** For maximum staining intensity we recommend the "UltraTek HRP Anti-Polyvalent Lab Pack" (ScyTek catalog# UHP125, see IFU for instructions) combined with the "DAB Chromogen/Substrate Bulk Pack (High Contrast)" (ScyTek catalog# ACV500, see IFU for instructions).


 Precautions:
 Contains Sodium Azide as a preservative (0.09% w/v).

 Do not pipette by mouth.
 Avoid contact of reagents and specimens with skin and mucous membranes.

 Avoid microbial contamination of reagents or increased nonspecific staining may occur.
 This product contains no hazardous material at a reportable concentration according to U.S. 29 CFR 1910.1200, OSHA Hazardous Communication Standard and EC Directive 91/155/EC.

### **References:**

- 1. Schwarting R, Gerdes J, Dürkop H, Falini B, Pileri S, Stein H. Ber-H2: A new anti-Ki-1 (CD30) monoclonal antibody directed at a formolresistant epitope. Blood 1989;74:1678-89.
- Warranty: No products or "Instructions For Use (IFU)" are to be construed as a recommendation for use in violation of any patents. We make no representations, warranties or assurances as to the accuracy or completeness of information provided on our IFU or website. Our warranty is limited to the actual price paid for the product. ScyTek Laboratories, Inc. is not liable for any property damage, personal injury, time or effort or economic loss caused by our products. Immunohistochemistry is a complex technique involving both histological and immunological detection methods. Tissue processing and handling prior to immunostaining can cause inconsistent results. Variations in fixation and embedding or the inherent nature of the tissue specimen may cause variations in results. Endogenous peroxidase activity or pseudoperoxidase activity in erythrocytes and endogenous biotin may cause non-specific staining depending on detection system used.





ScyTek Laboratories, Inc. 205 South 600 West Logan, UT 84321 U.S.A.



EC REP EmergoEurope (31)(0) 70 345-8570 Molsnstraat 15 2513 BH Hague, The Netherlands